BIOMAT Database Logo BIOMAT Database Logo

Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine--HGP-30-KLH. 1991

P H Naylor, and M B Sztein, and S Wada, and S Maurer, and D Holterman, and J E Kirkley, and C W Naylor, and B C Zook, and R A Hitzelberg, and C J Gibbs
Department of Biochemistry and Molecular Biology, George Washington University Medical Center, Washington, DC 20037.

Immunization with a synthetic HIV-1 p17 peptide analog (HGP-30; aa 85-115 of HIV p17), coupled to a carrier protein (KLH, keyhole limpet hemocyanin) given with alum as the adjuvant induces antibodies which cross-react with both HGP-30 and HIV p17 and clones of cytotoxic and helper T-cells which recognize HGP-30 and HIV p17. Proliferation of lymphocytes in response to HGP-30 has been observed in mice, in HIV-infected individuals and in healthy HIV-seronegative volunteers vaccinated with the p17-based synthetic peptide construct. Cytotoxic T-cell responses against EBV transformed, recombinant p17 pulsed targets were observed using antigen-expanded PBLs from HGP-30-KLH immunized individuals. These results are consistent with predictions that the HGP-30 domain of HIV p17 contains both T- and B-cell epitopes that are recognized by animals and humans. In preclinical toxicology studies in animals and in initial clinical trials in humans the synthetic peptide construct (HGP-30-KLH/alum) has been shown to be safe. This paper summarizes the preclinical immunogenicity and safety data for HGP-30-KLH and presents the initial results from the first Phase 1 clinical trial.

UI MeSH Term Description Entries
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D002679 Pan troglodytes The common chimpanzee, a species of the genus Pan, family HOMINIDAE. It lives in Africa, primarily in the tropical rainforests. There are a number of recognized subspecies. Chimpanzee,Chimpanzee troglodytes,Chimpanzee troglodyte,Chimpanzees,Pan troglodyte,troglodyte, Pan,troglodytes, Chimpanzee
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006041 Goats Any of numerous agile, hollow-horned RUMINANTS of the genus Capra, in the family Bovidae, closely related to the SHEEP. Capra,Capras,Goat
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D006433 Hemocyanins Metalloproteins that function as oxygen transport proteins in the HEMOLYMPH of MOLLUSKS and ARTHROPODS. They are characterized by two copper atoms, coordinated with HISTIDINE residues, that reversibly bind a single oxygen molecule; they do not contain HEME groups. Hemocyanin,alpha-Haemocyanin,alpha-Hemocyanin,alpha-Hemocyanins,alpha Haemocyanin,alpha Hemocyanin,alpha Hemocyanins
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

P H Naylor, and M B Sztein, and S Wada, and S Maurer, and D Holterman, and J E Kirkley, and C W Naylor, and B C Zook, and R A Hitzelberg, and C J Gibbs
Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
January 2004, Biopolymers,
P H Naylor, and M B Sztein, and S Wada, and S Maurer, and D Holterman, and J E Kirkley, and C W Naylor, and B C Zook, and R A Hitzelberg, and C J Gibbs
Cross-clade p17 peptide recognition by antisera to HGP-30, a 30-amino acid synthetic peptide antigen from HIV type 1 p17.
June 1998, AIDS research and human retroviruses,
P H Naylor, and M B Sztein, and S Wada, and S Maurer, and D Holterman, and J E Kirkley, and C W Naylor, and B C Zook, and R A Hitzelberg, and C J Gibbs
HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.
May 1995, Cellular and molecular biology (Noisy-le-Grand, France),
P H Naylor, and M B Sztein, and S Wada, and S Maurer, and D Holterman, and J E Kirkley, and C W Naylor, and B C Zook, and R A Hitzelberg, and C J Gibbs
Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study.
February 2014, Vaccine,
P H Naylor, and M B Sztein, and S Wada, and S Maurer, and D Holterman, and J E Kirkley, and C W Naylor, and B C Zook, and R A Hitzelberg, and C J Gibbs
Cell-mediated immunity against HGP-30, a group-specific peptide of HIV p17 in individuals infected with the AIDS virus.
January 1992, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
P H Naylor, and M B Sztein, and S Wada, and S Maurer, and D Holterman, and J E Kirkley, and C W Naylor, and B C Zook, and R A Hitzelberg, and C J Gibbs
A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue sub-unit vaccine in seronegative subjects.
August 1992, AIDS research and human retroviruses,
P H Naylor, and M B Sztein, and S Wada, and S Maurer, and D Holterman, and J E Kirkley, and C W Naylor, and B C Zook, and R A Hitzelberg, and C J Gibbs
Human immunodeficiency virus contains an epitope immunoreactive with thymosin alpha 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30.
May 1987, Proceedings of the National Academy of Sciences of the United States of America,
P H Naylor, and M B Sztein, and S Wada, and S Maurer, and D Holterman, and J E Kirkley, and C W Naylor, and B C Zook, and R A Hitzelberg, and C J Gibbs
HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals.
September 1990, Proceedings of the National Academy of Sciences of the United States of America,
P H Naylor, and M B Sztein, and S Wada, and S Maurer, and D Holterman, and J E Kirkley, and C W Naylor, and B C Zook, and R A Hitzelberg, and C J Gibbs
Protection by dendritic cells-based HIV synthetic peptide cocktail vaccine: preclinical studies in the SHIV-rhesus model.
March 2005, Vaccine,
P H Naylor, and M B Sztein, and S Wada, and S Maurer, and D Holterman, and J E Kirkley, and C W Naylor, and B C Zook, and R A Hitzelberg, and C J Gibbs
Synthetic peptide AT20 coupled to KLH elicits antibodies against a conserved conformational epitope from a major functional area of the HIV-1 matrix protein p17.
August 2008, Vaccine,
Copied contents to your clipboard!